IMNN Imunon, Inc.
Financings ·
Imunon's preliminary prospectus covers up to 20,000,000 shares, sold with warrants that could cover up to 70,000,000 more. The auditor's opinion on 2025 results includes substantial doubt about the company's ability to continue as a going concern.
Imunon will exchange $1,200,000 of a Streeterville note for 120 Series B preferred shares that cannot convert into common stock but carry an 8% return. Cash and cash equivalents were $6.9 million at June 30, 2026.
IMUNON has sold $10 million of preferred stock and two secured notes to Streeterville Capital, with half placed in a collateral account, to fund its Phase 3 OVATION 3 trial. The company used $13.9 million in operations in 2025.
Imunon (Nasdaq: IMNN) says the Nasdaq Hearings Panel notified it on August 27, 2025 that it meets the $1.00 minimum closing bid price. The stock will continue trading on the Nasdaq Capital Market.
The Nasdaq Hearings Panel confirmed compliance, so Imunon common stock will keep trading on The Nasdaq Capital Market. The company also pointed to a recent 15% stock dividend.
The panel granted the exception on July 11, 2025, so Imunon can regain compliance with the $1.00 minimum bid price and the stockholders' equity requirement. Stockholders also approved 2,000,000 more plan shares, bringing the plan's limit to 3,970,000.
Imunon, Inc. is a clinical-stage biotechnology company developing treatments that harness the body's natural mechanisms. It develops non-viral DNA technology across two modalities. TheraPlas codes for proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. PlaCCine codes for viral antigens that may support vaccines for infectious diseases. The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. The company says IMNN-001 has completed multiple clinical trials, including one Phase II trial (OVATION 2), and is currently conducting a Phase 3 trial (OVATION 3). Imunon also reports that it has completed dosing in a first-in-human study of its COVID-19 booster vaccine, IMNN-101. Its technology uses synthetic non-viral carriers to deliver plasmid DNA and mRNA, and the delivery system is designed to protect the DNA or mRNA from degradation. The company says it will advance these modalities directly or through partnership.
| Product or program | What it is | Stage |
|---|---|---|
| IMNN-001 | DNA-based immunotherapy for localized treatment of advanced ovarian cancer | Phase 3 (OVATION 3) ongoing |
| IMNN-101 | COVID-19 booster vaccine | first-in-human study dosing completed |
| TheraPlas | Non-viral DNA modality coding proteins and cytokines for solid tumors | |
| PlaCCine | Non-viral DNA modality coding viral antigens for infectious disease vaccines |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $7.8 million | $11.6 million |
| Net income (loss) | -$14.5 million | -$18.6 million |
| Cash from operations | -$13.9 million | -$18.9 million |
| Cash and equivalents | $8.8 million | $5.9 million |
Our latest story on this, dated Jul 14, 2025: "Imunon gets Nasdaq Hearing Panel exception after delisting determination". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 27, 2026: "Imunon files for share offering with 350% warrant coverage in four tranches". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 27, 2026: "Imunon files for share offering with 350% warrant coverage in four tranches". The story links the filing or release it is based on. Read the story.
Imunon, Inc. trades under the ticker IMNN on NASDAQ.
Imunon, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:CBO0; LSX:A41CNR.
The SEC Central Index Key (CIK) for Imunon, Inc. is 749647. Its filings are on SEC EDGAR.
5,611,403 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Imunon, Inc. under United States.
Our directory classifies Imunon, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Imunon, Inc. is US15117N7012.
aibio.space lists Imunon, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Imunon, Inc. is a clinical-stage biotechnology company developing treatments that harness the body's natural mechanisms. It develops non-viral DNA technology across two modalities.
IMNN-001: DNA-based immunotherapy for localized treatment of advanced ovarian cancer Stage: Phase 3 (OVATION 3) ongoing.
IMNN-101: COVID-19 booster vaccine Stage: first-in-human study dosing completed.
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,5.03,7.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,5.07,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio